HC Wainwright Reiterates Neutral Rating for Jazz Pharmaceuticals PLC (JAZZ)

HC Wainwright reissued their neutral rating on shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in a report published on Friday, Marketbeat reports. The firm currently has a $150.00 target price on the specialty pharmaceutical company’s stock, up from their previous target price of $144.00.

JAZZ has been the subject of several other research reports. UBS AG reduced their price target on shares of Jazz Pharmaceuticals PLC from $172.00 to $168.00 and set a buy rating for the company in a research report on Wednesday, November 8th. Janney Montgomery Scott reiterated a buy rating and issued a $192.00 price target (up previously from $180.00) on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Morgan Stanley assumed coverage on shares of Jazz Pharmaceuticals PLC in a research report on Thursday, October 5th. They issued an equal weight rating and a $155.00 price target for the company. Deutsche Bank AG set a $175.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a buy rating in a research report on Wednesday, August 9th. Finally, Cowen and Company reiterated an outperform rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $180.13.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) traded down $0.72 during mid-day trading on Friday, reaching $135.75. 56,680 shares of the company traded hands, compared to its average volume of 517,324. Jazz Pharmaceuticals PLC has a 1 year low of $99.28 and a 1 year high of $163.75. The stock has a market cap of $8,315.13, a P/E ratio of 17.40, a price-to-earnings-growth ratio of 0.82 and a beta of 1.00. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.94 and a current ratio of 3.10.

ILLEGAL ACTIVITY NOTICE: This report was posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://www.themarketsdaily.com/2017/11/14/hc-wainwright-reiterates-neutral-rating-for-jazz-pharmaceuticals-plc-jazz.html.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $153.52, for a total value of $153,520.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Patrick G. Enright sold 351 shares of the stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $148.40, for a total transaction of $52,088.40. Following the completion of the sale, the director now directly owns 1,717 shares in the company, valued at $254,802.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 2,351 shares of company stock worth $355,608. 4.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. First Republic Investment Management Inc. acquired a new stake in Jazz Pharmaceuticals PLC in the 3rd quarter valued at about $682,000. Magnetar Financial LLC grew its stake in Jazz Pharmaceuticals PLC by 27.7% in the 3rd quarter. Magnetar Financial LLC now owns 5,553 shares of the specialty pharmaceutical company’s stock valued at $812,000 after acquiring an additional 1,206 shares during the last quarter. Asset Management One Co. Ltd. boosted its stake in shares of Jazz Pharmaceuticals PLC by 771.1% during the 3rd quarter. Asset Management One Co. Ltd. now owns 90,988 shares of the specialty pharmaceutical company’s stock worth $13,307,000 after purchasing an additional 80,543 shares during the last quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp boosted its stake in shares of Jazz Pharmaceuticals PLC by 25.2% during the 3rd quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 29,059 shares of the specialty pharmaceutical company’s stock worth $4,250,000 after purchasing an additional 5,844 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 18.3% during the 3rd quarter. Epoch Investment Partners Inc. now owns 79,971 shares of the specialty pharmaceutical company’s stock worth $11,696,000 after purchasing an additional 12,385 shares during the last quarter. 88.91% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply